| protein
| IFN-gamma ( |
|
IFN-gamma receptor, IFN-gamma R ( |
|
synaptophysin, Syp ( |
|
AT1 receptor ( |
|
beta c chain of the GM-CSF receptor ( |
|
erythropoietin receptor, EPOR ( |
|
c-kit proto-oncogene ( |
|
PP2A, P13K, and Yes ( |
|
interleukin-12 receptor subunits beta1 and beta2 ( |
|
signal transducer and activator of transcription 5, STAT5 ( |
|
SHC (Src homology 2 domain containing) transforming protein, Shc ( |
|
signal transducer and activator of transcription 3, STAT3 ( |
|
SH2-Bbeta ( |
|
midkine-receptor ( |
|
tec protein tyrosine kinase, TEC ( |
|
insulin receptor, IR and the insulin-like growth factor-1 receptor, IGF1 ( |
|
tumor necrosis factor receptor 1, TNFR1 ( |
|
interleukin-5 (IL-5) receptor alpha and betac ( |
|
p125 focal adhesion kinase, FAK ( |
|
growth factor receptor-bound protein 10, Grb10 ( |
|
interleukin-12 receptor beta 2, IL-12R beta 2 ( |
|
cytokine-inducible SH2 protein 3, CIS3 ( |
|
growth hormone receptor, GHR ( |
|
chemokine (C-X-C motif) receptor 4, CXCR4 ( |
|
Skb1 and Hsl7p ( |
|
SH2-Containing protein tyrosine phosphatase-1, SHP-1 ( |
|
thyroid stimulating hormone receptor, TSHR ( |
|
SIRPalpha ( |
|
box 1-like motif in the cytoplasmic tail of CTLA-4 molecule ( |
|
cytokine receptor-like molecule 2, CRLM-2 ( |
|
signal transducing adaptor molecule (SH3 domain and ITAM motif) 1, STAM1 and signal transducing adaptor molecule (SH3 domain and ITAM motif) 2, STAM2 ( |
|
hTid-1(S) or hTid-1(L) ( |
|
protein tyrosine phosphatase, non-receptor type 1B, PTP1B ( |
|
protein tyrosine phosphatase-PEST, PTP-PEST ( |
|
G protein-coupled AngII type 1, AT(1) and protein tyrosine kinase 2 beta, PYK2B ( |
|
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), ERBB2 ( |
|
suppressor of cytokine signaling 1, SOCS1 ( |
|
Hes1 and Hes5 ( |
|
FABP4 in a fatty acid-dependent manner |
|
beta subunit of IFNgamma receptor and PKCepsilon |
|
VHL is a SOCS1-cooperative negative regulator of JAK2 |
|
CCDC80 is a JAK2-binding partner |
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| translocation
|
|
| |
in acute lymphoblastic leukemia | | tumoral
| fusion
|
|
| gain of function
| |
in leukemia or constitutively expressed in acute lymphoblastic leukemia with t(9;12) (p24;p13) and a chimeric fusion protein, 5' - ETV6 -JAK2 - 3' | | tumoral
| fusion
|
|
|
| |
BCR-JAK2 fusion, result of a t(9;22)(p24;q11.2) translocation in a chronic myeloid leukemia | | tumoral
|
| translocation
|
|
| |
t(8;9)(p22;p24), in in atypical chronic myeloid leukaemia with a PCM1-JAK2 fusion | | tumoral
| fusion
|
|
|
| |
with RPN1, in t(3;9)(q21;p24) in a patient with chronic idiopathic myelofibrosis (CIMF), a chronic myeloproliferative disorder | | constitutional
| germinal mutation
|
|
|
| |
V617F mutation is associated with thrombosis and pregnancy loss | | tumoral
| fusion
|
|
|
| |
with SSBP2 in a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia | | tumoral
|
| amplification
|
|
| |
V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia | | tumoral
| somatic mutation
|
|
|
| |
somatic activating mutation in 18p 100 of Down syndrome acute lymphoblastic leukaemia | | tumoral
| somatic mutation
|
|
|
| |
in pediatric acute lymphoblastic leukemia | | tumoral
|
| translocation
|
|
| |
t(4;9)(q21;p24) leading to a novel SEC31A-JAK2 fusion, in classical Hodgkin lymphoma | |
